We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

Vabysmo pre-filled syringe now also approved ... so there were more costs coming from other units into SG&A. Diabetes Care is one element that we integrated, just to mention example here, that's ...

Like Anderson, Graham is a veteran of Roche's Genentech unit in the US ... including the launches of Vabysmo (faricimab) for age-related macular degeneration (AMD) and lymphoma therapy Lunsumio ...

helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo. Roche sees high single-digit core profit growth in 2025 A Washington jury on Tuesday ordered Bayer ...

These findings underline Libtayo’s “potential to also transform the treatment of high-risk resectable cutaneous squamous cell carcinoma with adjuvant treatment,” Israel Low, clinical development unit ...

However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia’s (RBA ...

The letters of intent were signed with France's Colis Privé, a unit of CMA-CGM, UK-based Hived and Germany's DB Schencker and will add to sales for Renault and Renault Trucks (Volvo) brands.